10-Q: Azitra Inc. Reports First Quarter 2025 Results, Cites Ongoing Clinical Trials and Financial Uncertainty

Azitra Inc. announces its financial results for the first quarter of 2025, highlighting ongoing clinical trials for ATR-12 and ATR-04 while acknowledging substantial doubt about its ability to continue as a going concern.

Summary

• Azitra Inc. reported a net loss attributable to common shareholders of $3.07 million, or $0.23 per share, for the three months ended March 31, 2025, compared to a net loss of $2.93 million, or $4.32 per share, for the same period in 2024.
• General and administrative expenses increased by 24% to $1.85 million, while research and development expenses decreased by 15% to $1.25 million.
• The company completed follow-on public offerings in January and February 2025, generating net proceeds of $1.2 million and $561,000, respectively.
• As of March 31, 2025, Azitra had total assets of $5.9 million and working capital of $2.6 million, including $3.2 million in cash and cash equivalents.
• Management expresses substantial doubt about the company's ability to continue as a going concern due to its accumulated deficit of $60.6 million and the need for additional funding.
• The company is advancing its lead programs, ATR-12 for Netherton syndrome and ATR-04 for EGFRi-associated rash, through clinical trials, with initial safety results for ATR-12 expected in mid-2025.
• Azitra entered into a Purchase Agreement with Alumni Capital LP for up to $20 million in shares of common stock, issuing shares and warrants in April and May 2025.
• The company identified a material weakness in internal controls related to a lack of adequate segregation of accounting functions.

Sentiment

Score: 3

Explanation: The document presents a mixed picture. While the company is making progress with its clinical trials, the financial results are concerning, and the going concern warning raises significant red flags. The material weakness in internal controls further contributes to the negative sentiment.

Positives

• The company is actively advancing its lead programs, ATR-12 and ATR-04, through clinical trials.
• Azitra has partnerships with leading academic institutions like Carnegie Mellon University and the Fred Hutchinson Cancer Center.
• The company secured Pediatric Rare Disease Designation and Fast Track designation from the FDA for ATR-12 and ATR-04, respectively.
• Azitra has a proprietary platform and microbial library of approximately 1,500 unique bacterial strains for precision dermatology.

Negatives

• Azitra reported a net loss of $3.07 million for Q1 2025.
• Management expresses substantial doubt about the company's ability to continue as a going concern.
• The company identified a material weakness in internal controls related to segregation of accounting functions.
• The company's cash on-hand may not be sufficient to cover its proposed plan of operations over the next twelve months.

Risks

• The company's ability to continue as a going concern is uncertain due to its accumulated deficit and need for additional funding.
• Failure to secure additional financing could force the company to delay, limit, reduce, or terminate its research and development efforts.
• Changes in U.S. and international trade policies may adversely impact the company's business and operating results.
• The company is dependent on contract research organizations (CROs) and contract manufacturing organizations (CMOs), and interruptions in their operations could affect development programs.
• The company's product candidates require approval from the FDA or other regulatory agencies, and there is no assurance that necessary approvals will be received.

Future Outlook

The company expects to report initial safety results of the first patients dosed in its Phase 1b clinical trial for ATR-12 in mid-2025, with full results anticipated in the second half of 2025. The company expects to dose the first patient in the ATR-04 Phase 1/2 clinical trial in the first half of 2025. The company is planning to perform lead optimization and IND-enabling studies in 2025 to support an IND filing in early 2026.

Management Comments

• Management has determined there is substantial doubt about our ability to continue as a going concern based on our lack of revenue from commercial operations, significant losses, and the need to raise additional capital to support ongoing operations.

Industry Context

Azitra is operating in the competitive biopharmaceutical industry, focusing on precision dermatology. The company's approach involves leveraging engineered proteins and live biotherapeutic products, which aligns with the growing trend of personalized medicine and targeted therapies. The company faces competition from other companies developing treatments for skin diseases, including both large pharmaceutical companies and smaller biotech firms.

Comparison to Industry Standards

• It is difficult to compare Azitra's results directly to industry standards due to its early-stage clinical biopharmaceutical nature and lack of revenue-producing operations.
• Comparable companies in the early stages of clinical trials often experience similar financial profiles, with significant R&D expenses and reliance on external funding.
• The company's focus on precision dermatology and engineered live biotherapeutics aligns with innovative approaches in the industry, but also carries higher risks associated with novel technologies.
• The expression of doubt about the company's ability to continue as a going concern is a serious issue that requires immediate attention and action.

Corporate Governance

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings and the risk of further stock splits.
• Employees face uncertainty due to the company's going concern warning and potential need for cost-cutting measures.
• Customers (potential patients) may experience delays in the development and availability of new therapies if the company faces financial difficulties.
• Suppliers and creditors face the risk of non-payment if the company's financial situation deteriorates.

Next Steps

• The company plans to continue advancing its lead programs, ATR-12 and ATR-04, through clinical trials.
• Azitra intends to seek additional funding through various financing sources.
• The company will address the identified material weakness in internal controls by increasing staffing within its accounting infrastructure.
• The Board will continue to evaluate the need for a further reverse stock split.

Key Dates

Keywords

Azitra, clinical trials, Netherton syndrome, EGFRi, ATR-12, ATR-04, financial results, going concern, biopharmaceutical, dermatology